Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands
With the increasing pipeline of cell and gene therapies (CGTs) and the expected surge in the number of approvals, understanding the market access landscape becomes crucial for timely patient access. This study evaluates the challenges Dutch stakeholders encounter in CGT market access, offering insig...
Saved in:
| Main Authors: | Rimma Velikanova, Sharon Wolters, Hinko S. Hofstra, Maarten J. Postma, Cornelis Boersma |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-07-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2001-6689/12/3/15 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The EU Health Technology Assessment Regulation Halo Effect: Are Cross-Functional Teams Ready?
by: Sian Tanner, et al.
Published: (2025-01-01) -
Technology Assessment vs. Technology Appraisal—How to Strengthen the Science/Value Dichotomy with EU HTA?
by: Sandro Gsteiger, et al.
Published: (2024-11-01) -
Access in all areas? A roundup of developments in market access and health technology assessment: part 6
by: Annie Jullien Pannelay, et al.
Published: (2025-01-01) -
Pharmaceutical market access in emerging markets: concepts, components, and future
by: Anuj Kumar, et al.
Published: (2014-12-01) -
Conceptualisation and Role of Market Access in Pharmaceutical Industry: A Scoping Review
by: Clara Fatoye, et al.
Published: (2024-05-01)